The Top 10 MSOs of 2026: Moves, Innovation, and Performance
Market Analysis · By Headquarters · November 18, 2026
2026 was the year MSOs stopped competing mainly on store count and started competing on corporate structure. Medical cannabis moved to Schedule III in April, adult-use stayed in Schedule I, and the gap between those two facts is now driving ringfences, reverse splits, redomiciles, and distressed-asset deals across the industry. Operators did the work. Whether the market pays for it is a separate question: MSOS was up about 23% year to date in April on the rescheduling news and had given back all of it by early October, according to New Cannabis Ventures.
Every company on this list has now reported Q3 2026 results for the quarter ended September 30. We ranked them on three equal-weight lenses: moves (M&A, market entries, capital structure, listings), innovation (structural and regulatory firsts, new business models), and performance (growth, margins, cash flow, balance sheet). The ranking reflects the whole year, not just the quarter.
The Rankings at a Glance
| # | Company | Q3 revenue | YoY | Adj. EBITDA (margin) |
|---|---|---|---|---|
| 1 | Trulieve | $230M | -20% (deconsolidation) | $89M (39%) |
| 2 | Curaleaf | $352.7M | +10.9% | $77.6M (22.0%) |
| 3 | Green Thumb | $324.4M | +11.3% | $89.4M normalized (27.6%) |
| 4 | Vireo Growth | $253.7M | +177% (acquisitions) | $42.7M (16.8%) |
| 5 | Verano | $212.4M | +5% | $50.4M (24%) |
| 6 | Cresco Labs | $173M | +5% | $35M (20.2%) |
| 7 | TerrAscend | $68.2M | +4.8% | $17.5M (25.6%) |
| 8 | Jushi | $70.5M | +7% | $13.6M (19.3%) |
| 9 | Ascend Wellness | $130.0M | +4.2% | $31.1M (23.9%) |
| 10 | MariMed | $44.2M | +8.5% | $4.7M (10.5%) |
1. Trulieve
Move of the year: Trulieve became the first US MSO listed on the NYSE, trading from June 10, 2026. To get there it built a ringfence: adult-use and mixed operations went into a separate entity, Harvest Enterprises, which was deconsolidated so Trulieve reports as a medical-only company. Retained units convert back if listing rules change. (MJBizDaily, CRB Monitor)
Performance: The structure is now showing up in the numbers. Q3 revenue was $230M, down 20% from $288M, and the entire decline is the Harvest deconsolidation. Gross margin rose to 64% from 59%, adjusted EBITDA was $89M (39% margin versus 36% a year ago), operating cash flow was $74M, free cash flow was $45M, and cash ended at $327M. Net income attributable to common shareholders was $1M, against a $27M loss a year earlier. (Q3 8-K)
Trulieve also received final DEA registrations for its state-licensed medical dispensaries, repaid $65M of mortgage notes on its Jefferson County, Florida cultivation site ahead of a 2028 maturity, and domesticated to Delaware. The caveat: Florida adult-use is off the table until 2028, and the $406M GAAP net loss Trulieve booked in Q2 was a deconsolidation accounting charge, not an operating one.
2. Curaleaf
Moves: Curaleaf made the boldest bid of the year and lost it. Its unsolicited exchange offer for Aurora Cannabis, raised in October to an implied US$5.00 per share, ran into a board that recommended shareholders reject it and then signed a friendly deal to be acquired by Organigram for about C$561M. Curaleaf says its offer remains outstanding through December 4 unless extended, and that its own competition reviews are complete while Organigram's deal still needs approvals (Curaleaf statement). (CTV News, Curaleaf statement)
The rest of the year was steadier. Curaleaf bought the remaining 45% of Germany's Four20 Pharma for €76.5M, so it now owns 100% of Curaleaf International (Eastern Progress). It also switched to US domestic-issuer SEC reporting and picked up its first two registrations for standardized cannabis preparations in Spain.
Performance: Q3 revenue hit a record $352.7M (+10.9%), with domestic up about 8% to $294.0M and international up about 28% to $58.7M. Adjusted EBITDA was $77.6M (22.0%), but gross margin slipped to 48.3% and the net loss from continuing operations was $37.4M. Cash was $104.9M against $636.9M of debt, and management still targets roughly $150M of operating cash flow for the year. (Q3 8-K)
Curaleaf is the only MSO building a global business, and that is why it stays at number two despite the Aurora outcome.
3. Green Thumb Industries
GTI had the best operating quarter of the group. Revenue grew 11.3% to $324.4M, comparable sales rose 3.0% (the first increase since Q3 2024), normalized EBITDA was $89.4M (27.6% margin), operating cash flow was $58.3M, and cash ended at $316.0M against $277.3M of debt. (Q3 8-K)
Innovation: GTI's structural move is quieter than Trulieve's. In April it restructured RYTHM brand licensing from revenue-based fees to a fixed $70M per year, supporting RYTHM's Nasdaq listing, and GTI began consolidating RYTHM on October 10 after an ownership cap was removed. Gross margin reads 45.2%, but excluding $15.8M of RYTHM licensing fees it was 50.1%. Net loss was $4.8M, against $23.3M of income a year earlier that included the gain on the RYTHM IP sale.
GTI has also repurchased more than $80M of stock in 2026, extended its buyback for 12 months, received DEA registrations for certain medical licenses, and opened six RISE dispensaries in the quarter. It is the most conservative balance sheet in the group, and it returns cash instead of chasing deals.
4. Vireo Growth
Vireo was the consolidator of 2026. After the H1 run we covered in May (Schwazze, Hawthorne, Eaze, PharmaCann Colorado, FLUENT), the second half added an all-stock merger with Planet 13 (July), up to $35M for Cannabist assets, and a four-deal, roughly $208M entry into Ohio.
Q3 revenue was $253.7M (+177%), with pro forma retail revenue up 4.0% organically. Adjusted EBITDA was $42.7M, cash was $106.8M, and net debt was $186.2M excluding convertible debt. The company operates about 270 dispensaries across 15 states, launched a share repurchase program, and guided Q4 revenue to $250M to $265M (Q3 release).
Two things keep Vireo at four rather than higher. Margins compressed: Q3 adjusted EBITDA margin was 16.8%, down from 27.7% a year earlier. And the biggest 2026 deals are still pending: Planet 13 shareholders vote on December 10, and the Ohio and Cannabist transactions still need regulatory approvals. Credit bids and all-stock deals are a repeatable playbook. Integrating them is the test.
5. Verano
Verano put up a clean quarter: revenue of $212.4M (+5%, which the company describes as organic), gross margin of 47%, adjusted EBITDA of $50.4M (24%, against $53.1M and 26% a year ago), and operating cash flow of $49M, its highest in four years. Net loss narrowed to $4.1M from $43.8M. Cash was $102M, and the company raised 2026 capex guidance to $54M to $60M. It operates 163 stores in 13 states. (Q3 release)
Moves: Verano did a 1-for-5 reverse split in June explicitly to qualify for a major US exchange (Highly Capitalized) and says it is advancing listing preparations. It has not listed yet. It also holds one of five Virginia licenses and filed for DEA registration.
6. Cresco Labs
Cresco spent 2026 building Pennsylvania. It bought Laurel Harvest Labs (about $80M, March) and PharmaCann Penn's nine dispensaries ($50M, September), positioning itself as the state's leading medical retailer and wholesaler ahead of any adult-use flip (Business Wire). We covered the PA and Virginia setup earlier this fall.
Innovation: On October 30, shareholders approved with at least 94% support the creation of a new parent company ("TopCo"), a possible later redomicile from British Columbia to Delaware, and an extension of the multiple-voting-share sunset to the third anniversary of a US listing. It is a listing-prep structure, and no listing has happened.
Performance: Q3 revenue was $173M (+5%), adjusted EBITDA was $35M (20.2%, down from 24.1% a year ago), the net loss was $14.5M, and free cash flow was $21M. Cash was $76M against $454M of long-term notes and loans. (Q3 6-K)
7. TerrAscend
TerrAscend is the margin story. Q3 revenue was $68.2M (+4.8%), gross margin was 52.3%, adjusted EBITDA was $17.5M (25.6%), and free cash flow was $6.1M, the thirteenth consecutive positive FCF quarter. Net loss from continuing operations narrowed to $5.5M from $9.9M. Cash was $42.5M. (Q3 8-K)
Moves: Shareholders approved a share consolidation on August 24 as a step toward a major US listing, and the company closed its Aunt Mary's dispensary acquisition in Flemington, New Jersey (more than $10M in annualized revenue). Management says it is evaluating several more assets. (Special meeting notice)
8. Jushi
Jushi completed its redomicile from British Columbia to Nevada on July 30, grew to 42 dispensaries in eight states, and is one of five Virginia license holders, with adult-use sales scheduled to begin July 1, 2027. Q3 revenue was $70.5M (+7%), wholesale hit a second straight record at $9.7M (+40%), and adjusted EBITDA was $13.6M (19.3%). Net loss narrowed to $12.5M from $23.7M, but operating cash flow slipped to $3.5M and cash is $30.9M against $215.6M of gross debt. (Q3 8-K)
9. Ascend Wellness
Ascend's story is retail densification through a partner-store model: 56 stores at quarter end and 61 locations as of November 12, ahead of its 60-store year-end target. Q3 revenue was $130.0M (+4.2% year over year, +3.1% sequentially, inside its guided range), adjusted EBITDA was $31.1M (23.9%), and adjusted gross margin was 48.4%. Stockholders approved a reverse split on August 28 to support a possible US listing.
The balance sheet is the weak point. Net debt is $260.4M, interest expense was $22.0M in the quarter, the stockholders' deficit is $112.4M, and the net loss was $28.0M. Operating cash flow was $5.4M after a $19.1M semi-annual interest payment. Q4 guidance is 1% to 2% revenue growth at a margin consistent with Q3. (Q3 8-K)
10. MariMed
MariMed is the brand-licensing outlier. It posted record revenue of $44.2M (+8.5%) while expanding through branding rather than acquisitions: Betty's Eddies is the number one edibles brand in Massachusetts, Maryland, Illinois, and Delaware, entered Maine through a licensing agreement, and branded products now sit in 721 stores (+13%).
The financials are thinner. Adjusted EBITDA fell to $4.7M from $5.1M, gross margin was 38.8%, the net loss was $3.5M, and cash is $10.4M against about $78.2M of mortgages and notes. The company has also proposed a reverse split and a national exchange listing. (Q3 8-K)
Cautionary Tales
Three names fell off the list for the wrong reasons. The Cannabist Co. (formerly Columbia Care) entered CCAA and Chapter 15 proceedings in March and is being sold in pieces, including Virginia to Millstreet for $130M and a five-state package to Vireo (MJBizDaily). AYR Wellness saw its core assets in seven states go to its noteholders through foreclosure, with transfers closing through October 1 (AYR). Planet 13 reported revenue of $22.9M (-15%), exited California, and is being absorbed by Vireo.
The pattern is the same in all three: debt service outran margins that were already compressing.
What the Year Tells Operators
Structure became a competitive asset. Ringfences, TopCo vehicles, reverse splits, US redomiciles, and US-issuer reporting were the dominant moves among the top ten. Only Trulieve has completed one. The rest are waiting on rules that have not settled: the ALJ's broader rescheduling proceeding is still pending a recommended decision, and the April medical order is being challenged in the D.C. Circuit (Morgan Lewis).
Consolidation shifted from roll-ups to scavenging. Vireo's credit bids and stock deals, and Cresco's Pennsylvania purchases, are acquisitions of operators that could not carry their own debt.
Margins compressed almost everywhere. GTI's gross margin was 45.2% against 49.4% a year ago, Cresco's EBITDA margin fell almost four points, and Vireo's fell about 11 points year over year. TerrAscend and Trulieve held or expanded theirs.
Cash return and growth split the group. GTI and Trulieve return cash; Vireo and Curaleaf issue stock or take on debt to buy growth.
The restructurings are finance-operations problems. Deconsolidating adult-use operations requires carve-out financials that an auditor will accept. Holding medical and adult-use books apart means allocating shared costs between two tax treatments, which is the core of separating medical and adult-use books before December 31. A parent, a TopCo, a ringfenced entity, and a licensing vehicle all need consolidation logic that survives a state audit, which is the problem behind multi-entity financial consolidation. The operators on this list can staff for that. Everyone else in the market is looking at the same Schedule III split with a fraction of the finance headcount.
Two dates to watch: Planet 13's shareholders vote on the Vireo merger on December 10, and the federal hemp redefinition takes effect December 11 for naturally derived products unless Congress delays it again (lab-made cannabinoids lost hemp status November 12). Both will change the competitive map before the next earnings cycle.